Drug Type Diagnostic radiopharmaceuticals |
Synonyms- |
Target- |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 | |
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 | |
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 | |
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 |
Not Applicable | - | - | (Standard of care SRT) | kxpmkxnave(txrnvnyixs) = No significant differences were found in the rate of MIDs for all QoL domains at 12 and 24 months wdmhwmtnve (deymtbufjj ) View more | - | 01 Oct 2024 | |
Phase 3 | - | 764 | (pN0) | bcoeookkde(ykeiwwrxvu) = fumrvjsdck eewysrzknc (lcllfbtpaw ) | Positive | 08 Aug 2022 | |
(pN1) | bcoeookkde(ykeiwwrxvu) = gzydknrdzl eewysrzknc (lcllfbtpaw ) | ||||||
Not Applicable | Prostate-Specific-Antigen (PSA) | PSA doubling-time (DT) | Gleason Score (GS) ... View more | 97 | (High Pre-Test Probability Group) | qumbcreyvz(dbesuocyoh) = vaskflyfpr awvygculvd (bvwtqwsykc ) | Positive | 24 Sep 2021 | |
Not Applicable | - | - | czzrccqxht(svhyqloupr) = moxieaxoyi pbqalwbfss (tbquflanad ) View more | - | 15 May 2020 |